摘要
目的探究玻璃体腔注射康博西普对眼底病临床安全性和有效性的影响。方法选取2018年1月~2019年7月在我院治疗的68例眼底病患者为研究对象,采用随机数字表法分为对照组和观察组,各34例。对照组给予常规对症治疗,观察组在对照组基础上给予玻璃体腔注射康博西普治疗,比较两组临床治疗总有效率、临床症状改善时间、裸眼视力、黄斑中心凹视网膜厚度(CMT)、眼内压(IOP)及并发症发生情况。结果观察组治疗总有效率为97.05%,高于对照组的88.23%,差异有统计学意义(P<0.05);观察组平均视网膜水肿、新生血管、视网膜出血消失和视网膜厚度恢复正常时间均短于对照组,差异有统计学意义(P<0.05);治疗后,观察组裸眼视力高于对照组,CMT、IOP均小于对照组,差异有统计学意义(P<0.05);观察组并发症发生率为5.88%,与对照组的8.82%比较,差异无统计学意义(P>0.05)。结论玻璃体腔注射康博西普治疗眼底病总有效率高,可缩短临床症状改善时间,促进视力恢复,减小CMT和降低眼内压,应用安全性良好。
Objective To explore the effect of intravitreal injection of Conbosicept on the clinical safety and effectiveness of fundus diseases.Methods A total of 68 patients with fundus disease treated in our hospital from January 2018 to July 2019 were selected as the research objects.They were divided into control group and observation group by random number table method,with 34 cases in each group.The control group was given conventional symptomatic treatment,and the observation group was given intravitreal injection of Conbercept on the basis of the control group.The total effective rate of clinical treatment,clinical symptom improvement time,naked vision,macular foveal retinal thickness(CMT),eye Internal pressure(IOP)and complications.Results The total effective rate of treatment in the observation group was 97.05%,which was higher than 88.23%in the control group,the difference was statistically significant(P<0.05).The average retinal edema,neovascularization,disappearance of retinal hemorrhage,and retinal thickness return to normal in the observation group were shorter than those in the control group,the difference was statistically significant(P<0.05);after treatment,the naked eye vision of the observation group was higher than that of the control group,CMT,IOP All were smaller than the control group,the difference was statistically significant(P<0.05);the complication rate in the observation group was 5.88%,compared with 8.82%in the control group,the difference was not statistically significant(P>0.05).Conclusion Intravitreal injection of Conbosicept in the treatment of ocular fundus disease had a high overall effective rate,which could shorten the time of clinical symptom improvement,promote visual recovery,reduce CMT and lower intraocular pressure,and had good application safety.
作者
王兆雄
齐世欣
刘艳丽
于建国
WANG Zhao-xiong;QI Shi-xin;LIU Yan-li;YU Jian-guo(Department of Ophthalmology,People's Hospital of Baodi District/Baodi Clinical College of Tianjin Medical University,Tianjin 301800,China)
出处
《医学信息》
2020年第19期104-106,共3页
Journal of Medical Information
关键词
玻璃体
注射
康博西普
眼底病
Vitreous
Injection
Conbosicept
Fundus disease
